Navigation Links
Labopharm's NDA for Novel Trazodone Formulation accepted for review by FDA
Date:11/24/2008

- Action Date is July 18, 2009 -

LAVAL, QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its New Drug Application (NDA) for the Company's novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder, has been accepted for review and filed by the U.S. Food and Drug Administration (FDA). The action date under the Prescription Drug User Fee Act (PDUFA) is July 18, 2009.

Labopharm's NDA for its novel trazodone formulation is based on data from five pivotal pharmacokinetic studies and the positive results from its North American Phase III placebo controlled clinical trial (study 04ACL3-001), which enrolled more than 400 patients. The Agency advised the Company that one positive Phase III study is required for the formulation to be approved.

About Labopharm's Novel Trazodone Formulation and the Market for Antidepressants

One-half of patients being treated with antidepressants discontinue therapy within a year for reasons related to efficacy and/or tolerability, including delayed onset of therapeutic response, insomnia or sleep disturbance, agitation, exacerbation of anxiety, sexual dysfunction, weight gain and somnolence. Labopharm has developed a novel once-daily formulation of 150 mg and 300 mg of trazodone hydrochloride, a serotonin antagonist reuptake inhibitor (SARI), for the treatment of major depressive disorder (MDD) to address patient needs in the current depression landscape, providing an effective and convenient treatment option. In a Phase III placebo controlled study of patients with MDD, Labopharm's novel trazodone formulation demonstrated antidepressant efficacy, including rapid onset of therapeutic response, improved overall quality of sleep, a well t
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
2. Novel imaging technique reveals brain abnormalities that may play key role in ADHD
3. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
4. Novel IBS treatment developed at UB garners $8.5 million for seven-year clinical trial
5. Novel 4-drug combination proves safe for lung cancer treatment
6. Porter Novelli Named Agency of Record for Pharmavite(R) LLC
7. Completely novel action of insulin unveiled
8. Yo Mujer: Woman Escapes from Abusive Marriage in New Spanish-Language Novel
9. Moores UCSD Cancer Center studying novel leukemia vaccine for high-risk patients
10. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
11. Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Hayward, CA (PRWEB) July 30, 2014 ... and accessories at the lowest prices on the internet ... Lightning Cables in two lengths and two colors. These ... performance standards. , The high quality SF Cable ... 8-pin connector with digital signal delivering faster charging and ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... Some obese people have a genetic mutation that seems ... when they see food, researchers report. Gaining a ... pleasure and gratification at the sight of high-calorie foods ... overeating, the scientists suggested. More than one-third of ... by a combination of overeating, a lack of physical ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
Breaking Medicine News(10 mins):Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... metabolisms, which may help them generate the energy they need ... in the July Cell Metabolism , a Cell Press ... before detectable tumors form. By the same token, the studies ... metabolism shifts back before established tumors shrink. "This ...
... colorectal cancer risk, according to a new study in ... Gastroenterological Association (AGA) Institute. Folate is a water-soluble B ... that all forms and sources of folate were associated ... PhD, of the American Cancer Society and lead author ...
... By Serena Gordon HealthDay Reporter , TUESDAY, ... age 2 generally aren,t at risk for future behavioral or ... Kids who are speech-delayed, but don,t have any other developmental ... at age 2. But, the study found, those problems don,t ...
... , TUESDAY, July 5 (HealthDay News) -- People with ... increased risk of death, a new study indicates. ... January 2006 and September 2010 -- that looked at ... specified. Anorexics mistakenly believe they are fat and ...
... include Western lung cancer patients, first-line treatment with ... chemotherapy, according to research presented at the 14th ... by the International Association for the Study of ... kinase inhibitor (TKI) that targets the epidermal growth ...
... ingredients for long-term relationship satisfaction, according to an international ... committed relationships, but contrary to stereotypes, tenderness was more ... Also contrary to expectations of the researchers, men ... relationship, while women were more likely to report being ...
Cached Medicine News:Health News:Metabolic shift may offer early cancer clue 2Health News:High folate intake may reduce risk of colorectal cancer 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 2Health News:Tots Who Are 'Late Talkers' Typically Turn Out Fine: Study 3Health News:Eating Disorders Appear to Raise Risk of Death 2Health News:EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapy 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 2Health News:Couples report gender differences in relationship, sexual satisfaction over time 3
(Date:7/30/2014)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... the Jefferies 2014 Boston Healthcare Summit next week in ... on August 6, 2014 and will not be webcast. ... BioPharma manages a portfolio of patents and royalty assets, ... patents and license agreements with various biotechnology and pharmaceutical ...
(Date:7/30/2014)... Die Apex Medical Corporation (Apex, ... Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass sie ... anfechten werden. Dieses hat entschieden, dass die ... ResMed verletze. Apex weist darauf hin, dass ... Patente von ResMed Anfechtungen wegen Nichtigkeit eingeleitet ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- The global microbial identification ... methods, applications, end users, and geographies. Genotypic technology ... microbial identification market. This favorable growth is attributed ... and the time required for microbial identification along ... Furthermore, genotypic methods have high applications in clinical ...
Breaking Medicine Technology:PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6
... , TAMPA, Fla. , April 26 ... today that Zirgan™ (ganciclovir ophthalmic gel) 0.15% is now commercially ... Drug Administration in September 2009 , is a topical ... (dendritic ulcers).   , ...
... April 26 Aton Pharma, Inc., a ... acquired the U.S. marketing rights to LODOSYN® (carbidopa) tablets ... use with carbidopa-levodopa or with levodopa in the treatment ... administration of lower doses of levodopa with reduced nausea ...
Cached Medicine Technology:Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 2Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 3Aton Pharma Acquires Parkinson's Drug LODOSYN(R) (carbidopa) 4
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
Medicine Products: